Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis

BACKGROUND—The association of genetic polymorphisms and clopidogrel efficacy in patients with ischemic stroke or transient ischemic attack (TIA) remains controversial. We performed a systematic review and meta-analysis to assess the association between genetic polymorphisms, especially CYP2C19 genot...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2017-01, Vol.135 (1), p.21-33
Hauptverfasser: Pan, Yuesong, Chen, Weiqi, Xu, Yun, Yi, Xingyang, Han, Yan, Yang, Qingwu, Li, Xin, Huang, Li’an, Johnston, S Claiborne, Zhao, Xingquan, Liu, Liping, Zhang, Qi, Wang, Guangyao, Wang, Yongjun, Wang, Yilong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 33
container_issue 1
container_start_page 21
container_title Circulation (New York, N.Y.)
container_volume 135
creator Pan, Yuesong
Chen, Weiqi
Xu, Yun
Yi, Xingyang
Han, Yan
Yang, Qingwu
Li, Xin
Huang, Li’an
Johnston, S Claiborne
Zhao, Xingquan
Liu, Liping
Zhang, Qi
Wang, Guangyao
Wang, Yongjun
Wang, Yilong
description BACKGROUND—The association of genetic polymorphisms and clopidogrel efficacy in patients with ischemic stroke or transient ischemic attack (TIA) remains controversial. We performed a systematic review and meta-analysis to assess the association between genetic polymorphisms, especially CYP2C19 genotype, and clopidogrel efficacy for ischemic stroke or TIA. METHODS—We conducted a comprehensive search of the PubMed and EMBASE from their inceptions to June 24, 2016. Studies that reported clopidogrel-treated patients with stroke or TIA and with information on genetic polymorphisms were included. The endpoints were stroke, composite vascular events and any bleeding. RESULTS—Among 15 studies of 4,762 patients with stroke or TIA treated with clopidogrel, carriers of CYP2C19 loss-of-function alleles (*2, *3 and/or *8) were at increased risk of stroke compared with non-carriers (12.0% vs. 5.8%; risk ratio (RR)1.92, 95% confidence interval [CI]1.57-2.35; p
doi_str_mv 10.1161/CIRCULATIONAHA.116.024913
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1836731197</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1836731197</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3013-234af34224706b1b125419c054e9ff43c72d7623cb3e93b884cfe5b34c5f49413</originalsourceid><addsrcrecordid>eNqNUctu1DAUtRCIDoVfQGbHJsWvPIzEIopKO9JAUTtdR47nmjHjxFPbYZR_4KPJMAXEjtXVPY97pHsQekPJBaUFfdcsb5v7Vb1e3nyur-sjdkGYkJQ_QQuaM5GJnMunaEEIkVnJGTtDL2L8Nq8FL_Pn6IyVFSmkrBboxxUMkKzGX7ybeh_2Wxv7iNWwwY3ze7vxXwM4fGmM1UpP2PiAaz0mwMuot9DPzrsU_A7wTKyDGqKFIf0l65SU3r3HNb6bYoJeHbNu4buFw6-QT5BUpgblpmjjS_TMKBfh1eM8R_cfL9fNdba6uVo29SrTnFCeMS6U4YIxUZKiox1luaBSk1yANEZwXbJNWTCuOw6Sd1UltIG840LnRkhB-Tl6e7q7D_5hhJja3kYNzqkB_BhbWvGi5JTKcpbKk1QHH2MA0-6D7VWYWkraYxntv2UcsfZUxux9_Rgzdj1s_jh_f38WfDgJDt4lCHHnxgOEdgvKpe1_BPwEhKubag</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1836731197</pqid></control><display><type>article</type><title>Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Pan, Yuesong ; Chen, Weiqi ; Xu, Yun ; Yi, Xingyang ; Han, Yan ; Yang, Qingwu ; Li, Xin ; Huang, Li’an ; Johnston, S Claiborne ; Zhao, Xingquan ; Liu, Liping ; Zhang, Qi ; Wang, Guangyao ; Wang, Yongjun ; Wang, Yilong</creator><creatorcontrib>Pan, Yuesong ; Chen, Weiqi ; Xu, Yun ; Yi, Xingyang ; Han, Yan ; Yang, Qingwu ; Li, Xin ; Huang, Li’an ; Johnston, S Claiborne ; Zhao, Xingquan ; Liu, Liping ; Zhang, Qi ; Wang, Guangyao ; Wang, Yongjun ; Wang, Yilong</creatorcontrib><description>BACKGROUND—The association of genetic polymorphisms and clopidogrel efficacy in patients with ischemic stroke or transient ischemic attack (TIA) remains controversial. We performed a systematic review and meta-analysis to assess the association between genetic polymorphisms, especially CYP2C19 genotype, and clopidogrel efficacy for ischemic stroke or TIA. METHODS—We conducted a comprehensive search of the PubMed and EMBASE from their inceptions to June 24, 2016. Studies that reported clopidogrel-treated patients with stroke or TIA and with information on genetic polymorphisms were included. The endpoints were stroke, composite vascular events and any bleeding. RESULTS—Among 15 studies of 4,762 patients with stroke or TIA treated with clopidogrel, carriers of CYP2C19 loss-of-function alleles (*2, *3 and/or *8) were at increased risk of stroke compared with non-carriers (12.0% vs. 5.8%; risk ratio (RR)1.92, 95% confidence interval [CI]1.57-2.35; p&lt;0.001). Composite vascular events were also more frequent in carriers of CYP2C19 loss-of-function alleles compared with non-carriers (13.7% vs. 9.4%; RR1.51, 95%CI1.10-2.06; p=0.01), while bleeding rates were similar (2.4% vs. 3.1%; RR0.89, 95%CI0.58-1.35; p=0.59). There was no evidence of statistical heterogeneity among the included studies for stroke, but there was for composite vascular events. Genetic variants other than CYP2C19 were not associated with clinical outcomes except significant associations of PON1, P2Y12 and COX-1 with outcomes were observed in one study. CONCLUSIONS—Carriers of CYP2C19 loss-of-function alleles are at greater risk of stroke and composite vascular events compared with non-carriers among patients with ischemic stroke or TIA treated with clopidogrel.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIRCULATIONAHA.116.024913</identifier><identifier>PMID: 27806998</identifier><language>eng</language><publisher>United States: by the American College of Cardiology Foundation and the American Heart Association, Inc</publisher><subject>Alleles ; Cytochrome P-450 CYP2C19 - genetics ; Databases, Factual ; Genotype ; Humans ; Ischemic Attack, Transient - drug therapy ; Ischemic Attack, Transient - genetics ; Ischemic Attack, Transient - pathology ; Polymorphism, Genetic ; Risk ; Stroke - drug therapy ; Stroke - genetics ; Stroke - pathology ; Ticlopidine - analogs &amp; derivatives ; Ticlopidine - therapeutic use</subject><ispartof>Circulation (New York, N.Y.), 2017-01, Vol.135 (1), p.21-33</ispartof><rights>2016 by the American College of Cardiology Foundation and the American Heart Association, Inc.</rights><rights>2016 American Heart Association, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3013-234af34224706b1b125419c054e9ff43c72d7623cb3e93b884cfe5b34c5f49413</citedby><cites>FETCH-LOGICAL-c3013-234af34224706b1b125419c054e9ff43c72d7623cb3e93b884cfe5b34c5f49413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,3689,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27806998$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pan, Yuesong</creatorcontrib><creatorcontrib>Chen, Weiqi</creatorcontrib><creatorcontrib>Xu, Yun</creatorcontrib><creatorcontrib>Yi, Xingyang</creatorcontrib><creatorcontrib>Han, Yan</creatorcontrib><creatorcontrib>Yang, Qingwu</creatorcontrib><creatorcontrib>Li, Xin</creatorcontrib><creatorcontrib>Huang, Li’an</creatorcontrib><creatorcontrib>Johnston, S Claiborne</creatorcontrib><creatorcontrib>Zhao, Xingquan</creatorcontrib><creatorcontrib>Liu, Liping</creatorcontrib><creatorcontrib>Zhang, Qi</creatorcontrib><creatorcontrib>Wang, Guangyao</creatorcontrib><creatorcontrib>Wang, Yongjun</creatorcontrib><creatorcontrib>Wang, Yilong</creatorcontrib><title>Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>BACKGROUND—The association of genetic polymorphisms and clopidogrel efficacy in patients with ischemic stroke or transient ischemic attack (TIA) remains controversial. We performed a systematic review and meta-analysis to assess the association between genetic polymorphisms, especially CYP2C19 genotype, and clopidogrel efficacy for ischemic stroke or TIA. METHODS—We conducted a comprehensive search of the PubMed and EMBASE from their inceptions to June 24, 2016. Studies that reported clopidogrel-treated patients with stroke or TIA and with information on genetic polymorphisms were included. The endpoints were stroke, composite vascular events and any bleeding. RESULTS—Among 15 studies of 4,762 patients with stroke or TIA treated with clopidogrel, carriers of CYP2C19 loss-of-function alleles (*2, *3 and/or *8) were at increased risk of stroke compared with non-carriers (12.0% vs. 5.8%; risk ratio (RR)1.92, 95% confidence interval [CI]1.57-2.35; p&lt;0.001). Composite vascular events were also more frequent in carriers of CYP2C19 loss-of-function alleles compared with non-carriers (13.7% vs. 9.4%; RR1.51, 95%CI1.10-2.06; p=0.01), while bleeding rates were similar (2.4% vs. 3.1%; RR0.89, 95%CI0.58-1.35; p=0.59). There was no evidence of statistical heterogeneity among the included studies for stroke, but there was for composite vascular events. Genetic variants other than CYP2C19 were not associated with clinical outcomes except significant associations of PON1, P2Y12 and COX-1 with outcomes were observed in one study. CONCLUSIONS—Carriers of CYP2C19 loss-of-function alleles are at greater risk of stroke and composite vascular events compared with non-carriers among patients with ischemic stroke or TIA treated with clopidogrel.</description><subject>Alleles</subject><subject>Cytochrome P-450 CYP2C19 - genetics</subject><subject>Databases, Factual</subject><subject>Genotype</subject><subject>Humans</subject><subject>Ischemic Attack, Transient - drug therapy</subject><subject>Ischemic Attack, Transient - genetics</subject><subject>Ischemic Attack, Transient - pathology</subject><subject>Polymorphism, Genetic</subject><subject>Risk</subject><subject>Stroke - drug therapy</subject><subject>Stroke - genetics</subject><subject>Stroke - pathology</subject><subject>Ticlopidine - analogs &amp; derivatives</subject><subject>Ticlopidine - therapeutic use</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUctu1DAUtRCIDoVfQGbHJsWvPIzEIopKO9JAUTtdR47nmjHjxFPbYZR_4KPJMAXEjtXVPY97pHsQekPJBaUFfdcsb5v7Vb1e3nyur-sjdkGYkJQ_QQuaM5GJnMunaEEIkVnJGTtDL2L8Nq8FL_Pn6IyVFSmkrBboxxUMkKzGX7ybeh_2Wxv7iNWwwY3ze7vxXwM4fGmM1UpP2PiAaz0mwMuot9DPzrsU_A7wTKyDGqKFIf0l65SU3r3HNb6bYoJeHbNu4buFw6-QT5BUpgblpmjjS_TMKBfh1eM8R_cfL9fNdba6uVo29SrTnFCeMS6U4YIxUZKiox1luaBSk1yANEZwXbJNWTCuOw6Sd1UltIG840LnRkhB-Tl6e7q7D_5hhJja3kYNzqkB_BhbWvGi5JTKcpbKk1QHH2MA0-6D7VWYWkraYxntv2UcsfZUxux9_Rgzdj1s_jh_f38WfDgJDt4lCHHnxgOEdgvKpe1_BPwEhKubag</recordid><startdate>20170103</startdate><enddate>20170103</enddate><creator>Pan, Yuesong</creator><creator>Chen, Weiqi</creator><creator>Xu, Yun</creator><creator>Yi, Xingyang</creator><creator>Han, Yan</creator><creator>Yang, Qingwu</creator><creator>Li, Xin</creator><creator>Huang, Li’an</creator><creator>Johnston, S Claiborne</creator><creator>Zhao, Xingquan</creator><creator>Liu, Liping</creator><creator>Zhang, Qi</creator><creator>Wang, Guangyao</creator><creator>Wang, Yongjun</creator><creator>Wang, Yilong</creator><general>by the American College of Cardiology Foundation and the American Heart Association, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170103</creationdate><title>Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis</title><author>Pan, Yuesong ; Chen, Weiqi ; Xu, Yun ; Yi, Xingyang ; Han, Yan ; Yang, Qingwu ; Li, Xin ; Huang, Li’an ; Johnston, S Claiborne ; Zhao, Xingquan ; Liu, Liping ; Zhang, Qi ; Wang, Guangyao ; Wang, Yongjun ; Wang, Yilong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3013-234af34224706b1b125419c054e9ff43c72d7623cb3e93b884cfe5b34c5f49413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Alleles</topic><topic>Cytochrome P-450 CYP2C19 - genetics</topic><topic>Databases, Factual</topic><topic>Genotype</topic><topic>Humans</topic><topic>Ischemic Attack, Transient - drug therapy</topic><topic>Ischemic Attack, Transient - genetics</topic><topic>Ischemic Attack, Transient - pathology</topic><topic>Polymorphism, Genetic</topic><topic>Risk</topic><topic>Stroke - drug therapy</topic><topic>Stroke - genetics</topic><topic>Stroke - pathology</topic><topic>Ticlopidine - analogs &amp; derivatives</topic><topic>Ticlopidine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pan, Yuesong</creatorcontrib><creatorcontrib>Chen, Weiqi</creatorcontrib><creatorcontrib>Xu, Yun</creatorcontrib><creatorcontrib>Yi, Xingyang</creatorcontrib><creatorcontrib>Han, Yan</creatorcontrib><creatorcontrib>Yang, Qingwu</creatorcontrib><creatorcontrib>Li, Xin</creatorcontrib><creatorcontrib>Huang, Li’an</creatorcontrib><creatorcontrib>Johnston, S Claiborne</creatorcontrib><creatorcontrib>Zhao, Xingquan</creatorcontrib><creatorcontrib>Liu, Liping</creatorcontrib><creatorcontrib>Zhang, Qi</creatorcontrib><creatorcontrib>Wang, Guangyao</creatorcontrib><creatorcontrib>Wang, Yongjun</creatorcontrib><creatorcontrib>Wang, Yilong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pan, Yuesong</au><au>Chen, Weiqi</au><au>Xu, Yun</au><au>Yi, Xingyang</au><au>Han, Yan</au><au>Yang, Qingwu</au><au>Li, Xin</au><au>Huang, Li’an</au><au>Johnston, S Claiborne</au><au>Zhao, Xingquan</au><au>Liu, Liping</au><au>Zhang, Qi</au><au>Wang, Guangyao</au><au>Wang, Yongjun</au><au>Wang, Yilong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2017-01-03</date><risdate>2017</risdate><volume>135</volume><issue>1</issue><spage>21</spage><epage>33</epage><pages>21-33</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><abstract>BACKGROUND—The association of genetic polymorphisms and clopidogrel efficacy in patients with ischemic stroke or transient ischemic attack (TIA) remains controversial. We performed a systematic review and meta-analysis to assess the association between genetic polymorphisms, especially CYP2C19 genotype, and clopidogrel efficacy for ischemic stroke or TIA. METHODS—We conducted a comprehensive search of the PubMed and EMBASE from their inceptions to June 24, 2016. Studies that reported clopidogrel-treated patients with stroke or TIA and with information on genetic polymorphisms were included. The endpoints were stroke, composite vascular events and any bleeding. RESULTS—Among 15 studies of 4,762 patients with stroke or TIA treated with clopidogrel, carriers of CYP2C19 loss-of-function alleles (*2, *3 and/or *8) were at increased risk of stroke compared with non-carriers (12.0% vs. 5.8%; risk ratio (RR)1.92, 95% confidence interval [CI]1.57-2.35; p&lt;0.001). Composite vascular events were also more frequent in carriers of CYP2C19 loss-of-function alleles compared with non-carriers (13.7% vs. 9.4%; RR1.51, 95%CI1.10-2.06; p=0.01), while bleeding rates were similar (2.4% vs. 3.1%; RR0.89, 95%CI0.58-1.35; p=0.59). There was no evidence of statistical heterogeneity among the included studies for stroke, but there was for composite vascular events. Genetic variants other than CYP2C19 were not associated with clinical outcomes except significant associations of PON1, P2Y12 and COX-1 with outcomes were observed in one study. CONCLUSIONS—Carriers of CYP2C19 loss-of-function alleles are at greater risk of stroke and composite vascular events compared with non-carriers among patients with ischemic stroke or TIA treated with clopidogrel.</abstract><cop>United States</cop><pub>by the American College of Cardiology Foundation and the American Heart Association, Inc</pub><pmid>27806998</pmid><doi>10.1161/CIRCULATIONAHA.116.024913</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 2017-01, Vol.135 (1), p.21-33
issn 0009-7322
1524-4539
language eng
recordid cdi_proquest_miscellaneous_1836731197
source MEDLINE; American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals
subjects Alleles
Cytochrome P-450 CYP2C19 - genetics
Databases, Factual
Genotype
Humans
Ischemic Attack, Transient - drug therapy
Ischemic Attack, Transient - genetics
Ischemic Attack, Transient - pathology
Polymorphism, Genetic
Risk
Stroke - drug therapy
Stroke - genetics
Stroke - pathology
Ticlopidine - analogs & derivatives
Ticlopidine - therapeutic use
title Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T15%3A40%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetic%20Polymorphisms%20and%20Clopidogrel%20Efficacy%20for%20Acute%20Ischemic%20Stroke%20or%20Transient%20Ischemic%20Attack:%20A%20Systematic%20Review%20and%20Meta-analysis&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=Pan,%20Yuesong&rft.date=2017-01-03&rft.volume=135&rft.issue=1&rft.spage=21&rft.epage=33&rft.pages=21-33&rft.issn=0009-7322&rft.eissn=1524-4539&rft_id=info:doi/10.1161/CIRCULATIONAHA.116.024913&rft_dat=%3Cproquest_cross%3E1836731197%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1836731197&rft_id=info:pmid/27806998&rfr_iscdi=true